Best in Biotech 15 May 2023
The six most advanced microbiome players aiming for the gut
After decades of research, gut microbiome therapies are beginning to reach the market. Here are six of the companies harnessing…
Jonathan Smith
About
Reporter for Labiotech. I hail from the UK. I was born in Bristol, studied Neuroscience in the University of Bristol, and trained mice in Eisai, Hertfordshire, for one year. I then tickled locusts for my Ph.D. at the University of Leicester, before eventually ending up here!
Out of the office, I travel, play video games and board games, drink beer and play the piano.
Articles by Jonathan Smith
In Depth 6 Mar 2023
The biggest private biotech investments in February 2023
The companies Aera Therapeutics, Hemab and Loam Bio bagged the biggest biotech investments in February 2023. Around the world, gene…
In Depth 6 Feb 2023
The biggest private biotech investments in January 2023
The companies Asimov, BioRay Pharmaceuticals and Colossal Biosciences bagged the biggest biotech investments in January 2023. Around the world, synthetic…
Best in Biotech 12 Jan 2023
The biggest biotech trends that will shape 2023
2023 has begun at full throttle. We have collected seven major biotech trends that industry experts are keeping an eye…
ADVERTISEMENT
In Depth 9 Jan 2023
The biggest private biotech investments in December 2022
The companies Apogee Therapeutics, Pulmocide and Qitan Technology bagged the biggest biotech investments in December 2022. Around the world, immunology…
In Depth 5 Jan 2023
Navignostics maps tumor proteomes to improve precision oncology
New cancer drugs are entering the market every year, but it’s hard to know which patients they benefit the most.…
In Depth 22 Dec 2022
10 biotech companies to watch in 2023
2022 is coming to an end. Here is a list of biotech companies from around the world that we are…
In Depth 20 Dec 2022
Ebvallo approval ushers in off-the-shelf T-cell immunotherapies
Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics' Ebvallo…
Startup Scout 19 Dec 2022
Green Bioactives grows medicines in plant cells
Though plants may hold the key to new, effective medicines, sourcing these compounds sustainably is difficult. Green Bioactives devises eco-friendly…
In Depth 15 Dec 2022
To avoid stagnation, the EU must refine its ATMP regulation
Over the decades, the EU has spearheaded the adoption of advanced therapy medicinal products (ATMPs) such as cell and gene…
ADVERTISEMENT
Interview 14 Dec 2022
Sibylla Biotech: how physicists met biologists to discover new drugs
Discovering new drugs remains an inefficient, trial and error-based process. The founding team behind the Italian startup Sibylla Biotech explain…
Startup Scout 13 Dec 2022
Biomemory is making DNA hard drives cheap and sustainable
The world is running out of ways to store the mountains of data we produce. Biomemory is creating DNA-based hard…
In Depth 5 Dec 2022
The biggest private biotech investments in November 2022
The companies Emalex Biosciences, Osler Diagnostics and TauRx Pharmaceuticals bagged the biggest biotech investments in November 2022. Around the world,…
Best in Biotech 1 Dec 2022
Five apps powering the future of at-home HIV tests
The smartphone revolution is providing a promising tool to combat the human immunodeficiency virus (HIV) epidemic. We’ve listed five HIV…
Interview 29 Nov 2022
LAG-3: The next big checkpoint inhibitor target
Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in the treatment of cancer. The…
Interview 28 Nov 2022
Breaking barriers to gene therapies for childhood rare diseases
The majority of known rare genetic diseases affect children, and gene therapies could help them live normal lives. Miquel Vila-Perelló,…
ADVERTISEMENT
News and Trends 24 Nov 2022
Gene therapy approval “game changer” in hemophilia B treatment
The approval of CSL's gene therapy Hemgenix has ushered in a new era for hemophilia B treatment. With the addition…
Interview 23 Nov 2022
What recent mixed clinical results can teach about Alzheimer’s disease
2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon,…
Startup Scout 21 Nov 2022
Osivax is designing future-proof influenza and Covid vaccines
Viruses causing influenza and COVID-19 continually evolve to escape our vaccine protections. The French firm Osivax is developing vaccines that…
Best in Biotech 17 Nov 2022
The hottest private biotech companies in Canada
Canada is well known for biotech innovations, with expertise in genomics, cell therapies and liquid biopsy. Here is a list…